T Cell-Mediated Nasal Hyperresponsiveness in Allergic Rhinitis

被引:13
作者
Kaminuma, Osamu [1 ,2 ,3 ,4 ]
Nishimura, Tomoe [2 ]
Saeki, Mayumi [2 ]
Mori, Akio [2 ,3 ]
Hiroi, Takachika [2 ]
机构
[1] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan
[2] Tokyo Metropolitan Inst Med Sci, Allergy & Immunol Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan
[3] Sagamihara Natl Hosp, Natl Hosp Org, Clin Res Ctr Allergy & Rheumatol, Sagamihara, Kanagawa 2520392, Japan
[4] Univ Yamanashi, Ctr Life Sci Res, 1110 Shimokato, Yamanashi 4093898, Japan
基金
日本学术振兴会;
关键词
eosinophil; immunoglobulin E; mast cell; nasal lavage; T cell; ANIMAL-MODELS; MAST-CELLS; INFLAMMATION; CHALLENGE; INCREASE; MICE;
D O I
10.1248/bpb.b18-01021
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Allergic rhinitis patients suffer various symptoms such as sneezing, runny nose, and nasal congestion. As disease severity and chronicity progress, nasal hyperresponsiveness (NHR) develops in those patients. During the generation of a mouse allergic rhinitis model, we discovered that immunized mice developed NHR upon repeated nasal antigen challenge. Using genetically modified mice and an originally developed T cell-transferred mouse model, we confirmed the critical role of CD4(+) T cells after differentiation into several helper subsets in NHR. On the other hand, immunoglobulin E/mast cell-dependent responses that are critical for evoking nasal symptoms and eosinophils that accumulate in allergic inflammation sites were dispensable. A steroid, but not drugs targeting mast cell-derived mediators, was effective in alleviating NHR. The possible generation of a new means to treat allergic rhinitis by targeting T cell-derived NHR-inducing factors is suggested.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 17 条
  • [1] Animal Models of Allergic Airways Disease: Where Are We and Where to Next?
    Chapman, David G.
    Tully, Jane E.
    Nolin, James D.
    Janssen-Heininger, Yvonne M.
    Irvin, Charles G.
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2014, 115 (12) : 2055 - 2064
  • [2] Pathogenesis of rhinitis
    Eifan, A. O.
    Durham, S. R.
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2016, 46 (09) : 1139 - 1151
  • [3] CD4+ T-cell subsets in inflammatory diseases: beyond the Th1/Th2 paradigm
    Hirahara, Kiyoshi
    Nakayama, Toshinori
    [J]. INTERNATIONAL IMMUNOLOGY, 2016, 28 (04) : 163 - 171
  • [4] Successful transfer of late phase eosinophil infiltration in the lung by infusion of helper T cell clones
    Kaminuma, O
    Mori, A
    Ogawa, K
    Nakata, A
    Kikkawa, H
    Naito, K
    Suko, M
    Okudaira, H
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1997, 16 (04) : 448 - 454
  • [5] Kanthawatana S, 1997, ASIAN PAC J ALLERGY, V15, P65
  • [6] KITAMURA Y, 1978, BLOOD, V52, P447
  • [7] Effects of anti-allergic drugs on T cell-mediated nasal hyperresponsiveness in a murine model of allergic rhinitis
    Nishimura, Tomoe
    Kaminuma, Osamu
    Saeki, Mayumi
    Kitamura, Noriko
    Gotoh, Minoru
    Mori, Akio
    Hiroi, Takachika
    [J]. ALLERGOLOGY INTERNATIONAL, 2018, 67 : S25 - S31
  • [8] Essential Contribution of CD4+ T Cells to Antigen-Induced Nasal Hyperresponsiveness in Experimental Allergic Rhinitis (Publication with Expression of Concern)
    Nishimura, Tomoe
    Kaminuma, Osamu
    Saeki, Mayumi
    Kitamura, Noriko
    Matsuoka, Kunie
    Yonekawa, Hiromichi
    Mori, Akio
    Hiroi, Takachika
    [J]. PLOS ONE, 2016, 11 (01):
  • [9] Transient contribution of mast cells to pulmonary eosinophilia but not to hyper-responsiveness
    Ogawa, K
    Kaminuma, O
    Kikkawa, H
    Nakata, A
    Asahina, M
    Egan, RW
    Akiyama, K
    Mori, A
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2002, 32 (01) : 140 - 148
  • [10] Japanese guidelines for allergic rhinitis 2017
    Okubo, Kimihiro
    Kurono, Yuichi
    Ichimura, Keiichi
    Enomoto, Tadao
    Okamoto, Yoshitaka
    Kawauchi, Hideyuki
    Suzaki, Harumi
    Fujieda, Shigeharu
    Masuyama, Keisuke
    [J]. ALLERGOLOGY INTERNATIONAL, 2017, 66 (02) : 205 - 219